48 results about "Bone marrow source" patented technology

Disclosed are methods of treating traumatic brain injury in a subject by administering a therapeutic MSC secretome product made by a method comprising culturing bone marrow-derived MSCs under conditions that include oxygen tension below 5% and a culture media with a pH below 7.

Disclosed are methods of treating infertility or increasing fertility of a female subject by administering a therapeutic MSC secretome product made by a method comprising culturing bone marrow-derived MSCs under conditions that include oxygen tension below 5% and a culture media with a pH below 7.

Disclosed are methods of treating perianal fistula a subject by administering a therapeutic MSC secretome product made by a method comprising culturing bone marrow-derived MSCs under conditions that include oxygen tension below 5% and a culture media with a pH below 7.

Disclosed are methods of improving perioral and face fat graft retention in a subject by administering a therapeutic MSC secretome product made by a method comprising culturing bone marrow-derived MSCs under conditions that include oxygen tension below 5% and a culture media with a pH below 7.

The invention relates to a tumor neoantigen DC vaccine based on a cytoskeleton as well as a preparation method and application thereof, and belongs to the technical field of biological medicines. The neoantigen DC vaccine comprises a cell scaffold which is formed by a polymer material and has a porous spongy structure, bone marrow-derived dendritic cells BMCD and tumor neoantigen which are dispersed in the cell scaffold, and an active substance which is cross-linked with the cell scaffold and is used for promoting proliferation and differentiation of T cells or B, the active substance comprises CCL21, and the tumor neoantigen is derived from liver cancer cells. According to the novel antigen DC vaccine based on the cytoskeleton, recruitment of T cells is realized in vivo, interaction of DC-T is promoted, and novel antigen specific T cells are efficiently induced and activated; moreover, the cell scaffold can simulate an immune microenvironment of lymph nodes through in-vivo implantation, so that an anti-tumor effect based on neoantigen DC vaccine excitation is realized.

The invention provides application of apoptotic cell pretreated macrophages in preparation of an osteoarthritis treatment preparation, a cell preparation and a preparation method, and relates to the technical field of biomedicine.In the embodiment of the invention, based on a mouse development model and an osteoarthritis (OA) model, it is found that in the area away from the cartilage surface, the apoptotic cell pretreated macrophages are subjected to apoptotic cell pretreatment, and the apoptotic cell pretreated macrophages are subjected to apoptotic cell pretreatment in the area away from the cartilage surface; in the macrophages, the content of the interment-related LAMP1 protein is obviously higher than that of the macrophages close to the cartilage surface area, and the expression results of TGF-beta 1 and LRG1 are respectively opposite and consistent with those of the LAMP1. The invention also finds that after the chemotactic effect of apoptotic cells on macrophages is weakened, the cellular burial effect is limited, and the cartilage matrix development disorder is caused. Based on development process inspiration, the invention provides a treatment strategy: bone marrow-derived macrophages pretreated by apoptotic cells are injected into articular cavities, and a good cartilage regeneration treatment effect can be achieved in a mouse arthritis model. In addition, the bone marrow-derived macrophages pretreated by apoptotic cells can still express TGF-beta1 after being injected into the body for 3 days, so that the effect of continuously promoting cartilage regeneration is achieved.

The invention discloses hydrogel for remodeling an aging microenvironment and promoting rotator cuff injury repair and a preparation method of the hydrogel. The hydrogel comprises ordered hydroxyapatite super-long nanowire / gelatin-hyaluronic acid composite hydrogel and quercetin loaded in the ordered hydroxyapatite super-long nanowire / gelatin-hyaluronic acid composite hydrogel. According to the ordered hydroxyapatite ultra-long nanowire (AHNW) / gelatin-hyaluronic acid (GH) hydrogel compound loaded with Quercetin, the repairing capacity of bone marrow-derived mesenchymal stem cells (BMSCs) and tendon-derived stem cells (TDSCs) is improved by remodeling an aging microenvironment, so that tendon-bone healing is promoted, the integration effect is improved, and the application prospect is wide. A new treatment strategy is provided for the patient with the rotator cuff injury, especially the patient with the osteoporosis.

A polyclonal antibody composition specifically binds the pTonB epitope (SEQ ID NO: 11) from Acinetobacter baumannii and is elicited by immunization with a multi-epitope antigen comprising thioredoxin leader, rigid linker, and kernels including SEQ ID NOs: 6, 7, 11, 12, and 8. These antibodies enhance opsonophagocytic killing of A. baumannii Ci79 via classical complement activation and Fey receptor-mediated phagocytosis by bone marrow-derived macrophages. Absorption of pTonB-specific antibodies reduces killing by >70%, confirming epitope dominance. Passive transfer of the composition protects >60% of mice in a lethal intranasal challenge model. Pharmaceutical compositions, treatment methods (alone or with antibiotics like colistin), prophylactic uses, diagnostic kits, and polyclonal compositions are disclosed for combating multidrug-resistant A. baumannii infections.

The present invention discloses the use of CSF1-CD47 in the preparation of an early transplantation immune rejection inhibitor. The inventors have found that CSF1 / CD47 NVs can specifically bind to the corresponding ligands CSF1R and SIRPα expressed by macrophages, and on the one hand, promote bone marrow-derived monocytes to Ly6G by enhancing the CSF1 / CSF1R signaling pathway. ‑ Ly6C ‑ On the other hand, it inhibits macrophage differentiation by inhibiting macrophage phagocytosis of nanovesicles by enhancing the CD47 / SIRPα signaling pathway, prolonging the action time of CSF1, and also inhibiting the phagocytosis and antigen presentation of mononuclear macrophages to transplant antigens. In the in vivo mouse heart transplant model, CSF1 / CD47 NVs also showed more significant effects than single-target NVs in alleviating immune rejection and prolonging the survival curve of transplanted hearts. The combined use of CSF1 / CD47 can effectively alleviate early immune rejection of transplantation and improve the success rate of organ transplantation.

The invention provides a platelet drug-loaded vesicle loaded with pecetinib and application thereof, and relates to the technical field of biological medicines. On the premise of retaining the targeting property of the platelet vesicles, the properties of surface chemistry, charge, shape, size and the like of the platelet drug-loaded vesicles are controlled, so that the platelet drug-loaded vesicles can reach a tumor microenvironment through a vascular endothelial cell barrier to play a role. After intravenous injection of the platelet drug-loaded vesicle, migration and activation of bone marrow-derived suppressor cells in a tumor microenvironment can be significantly inhibited, which indicates that the platelet drug-loaded vesicle passes through a vascular endothelial cell barrier and successfully releases pecetinib in the tumor microenvironment; plasma protein in blood does not affect drug release of the platelet drug-loaded vesicle provided by the invention. Therefore, the platelet drug-loaded vesicle disclosed by the invention has good targeting property and drug release ability, is low in production cost and easy to prepare, and can save the research and development cost of a drug delivery system.

The invention belongs to the technical field of medical materials and tissue regeneration engineering, and provides a composite hydrogel prepolymerization solution and application thereof, and composite hydrogel and application thereof. The composite hydrogel pre-polymerization liquid provided by the invention is prepared from the following components in concentration: 5 to 10 w / v percent of methacrylic anhydride gelatin, 1 to 4 w / v percent of methacrylated hyaluronic acid, 0.5 to 1.5 w / v percent of hectorite, 0.5 to 1.5 w / v percent of a photoinitiator and 20 to 100 nmol / L of sphingosine-1-phosphoric acid loaded nano vesicles based on sphingosine-1-phosphoric acid, the nano vesicles are formed by bone marrow-derived macrophages. The composite hydrogel formed by the composite hydrogel pre-polymerization liquid has good biocompatibility and controllable release performance, can form a stable barrier environment on a wound surface, and significantly accelerates the wound surface healing process through the dual effects of immune regulation and revascularization.

The invention belongs to the technical field of biological medicines, and particularly relates to application of emipril in preparation of a medicine for improving choroidal neovascularization related diseases. The invention aims to solve the problems of strong invasiveness and limited curative effect of the existing therapy. It is found that emipril can achieve differential regulation and control on a CD26 system in vivo, that is, the enzyme activity of CD26 in bone marrow is improved, the enzyme activity of CD26 in peripheral blood is reduced, the concentration gradient of stromal cell-derived factor-1 can be established between the bone marrow and the peripheral blood through differential regulation and control, and the concentration gradient of the stromal cell-derived factor-1 can be further improved. The bone marrow-derived cells are driven to homing to eye lesions and differentiate into repair cells, so that eye diseases are repaired or improved, meanwhile, the collection and migration of bone marrow-derived macrophages to CNV regions can be increased, and the anti-inflammatory effect is achieved. According to the application, an endogenous repair mechanism is activated through non-invasive administration, and a safer and more effective treatment method is provided for related eye diseases.

The invention relates to the field of biological medicine, in particular to a lipidosome hybridized nano-vesicle vaccine loaded with piperazosin, a preparation method of the lipidosome hybridized nano-vesicle vaccine and application of the lipidosome hybridized nano-vesicle vaccine in preparation of anti-tumor drugs. The lipidosome hybrid nano-vesicle vaccine loaded with the prazosin, disclosed by the invention, can be used for inhibiting autophagy and inducing the death of immunogenic cells of tumors. The pirazosin-loaded liposome hybrid nano-vesicle vaccine can activate and promote the maturation of bone marrow-derived dendritic cells, the expression of costimulatory factors CD80 and CD86 is obviously increased, and the antigen presentation is better promoted. The lipidosome hybrid nano-vesicle vaccine loaded with the prazosin can promote infiltration of mature dendritic cells and T cells in tumor tissues, can remarkably inhibit tumor growth, can remodel a tumor microenvironment as a tumor vaccine, and effectively improves the immunotherapy effect.

Disclosed are methods of treating perianal fistula a subject by administering a therapeutic MSC secretome product made by a method comprising culturing bone marrow-derived MSCs under conditions that include oxygen tension below 5% and a culture media with a pH below 7.

The invention belongs to the technical field of biological medicines, and particularly relates to application of an antiviral drug acyclovir in preparation of a tumor immunotherapy drug. According to the invention, acyclovir is utilized to induce macrophages to become an M1 phenotype, the phagocytic function and the antigen presentation capability of the macrophages are enhanced, and the maturation of dendritic cells is promoted, so that the anti-tumor effect is realized. In an effective concentration which is non-toxic to a macrophage line RAW264.7, acyclovir significantly promotes phenotype transformation of macrophages to M1, and significantly enhances the cell phagocytic ability and antigen presentation ability of the macrophages. Meanwhile, the acyclovir in an effective concentration can also remarkably promote maturation of bone marrow-derived dendritic cells, so that new application of the acyclovir in the field of tumor immunotherapy is found. According to the method, the application range of acyclovir and immune cell immunotherapy is expanded, and a new feasible clinical treatment scheme is provided for anti-tumor immunotherapy.

The invention discloses application of curcumenone in preparation of a medicine for preventing and treating ischemia-reperfusion injury. The invention proposes and verifies that the caramel curcumenone can be used for preventing and treating the hepatic ischemia reperfusion injury for the first time, and the compound can effectively protect hepatic tissues and avoid liver function damage by inhibiting the oxidative stress level of the hepatic tissues after ischemia reperfusion, avoiding cell ferroptosis and improving bone marrow-derived macrophages, so that the caramel curcumenone can be used for preventing and treating the hepatic ischemia reperfusion injury. The invention provides a novel medicine with great application potential for preventing and treating ischemia reperfusion injury.

Disclosed are methods of treating infertility or increasing fertility of a female subject by administering a therapeutic MSC secretome product made by a method comprising culturing bone marrow-derived MSCs under conditions that include oxygen tension below 5% and a culture media with a pH below 7.

To provide solutions to the problems of conventional methods for constructing a three-dimensional structure (organ primordium) by co-culturing functional cells with endothelial cells derived from umbilical codes and mesenchymal cells derived from bone marrow, the problems being: [1] donor dependent quality diversity; [2] limited proliferation capability of cell sources; and [3] difficulty in guaranteeing immunocompatibility because of different cell sources.SOLUTION: Disclosed is an organ bud prepared from vascular cells, mesenchymal cells and tissue or organ cells, where the vascular cells, mesenchymal cells and tissue or organ cells have been induced from pluripotent stem cells respectively. Also disclosed is a method for preparing an organ bud, the method comprising culturing the vascular cells, mesenchymal cells and tissue or organ cells in vitro, where the vascular cells, mesenchymal cells and tissue or organ cells have been induced from pluripotent stem cells respectively.SELECTED DRAWING: Figure 3

The present disclosure relates to a composition for three-dimensional cell and / or organoid culture, comprising a phase-changing matrix comprising a partially ordered polypeptide, and a plurality of cells encapsulated in the matrix. In embodiments, the plurality of cells comprises one or more cell types, including at least one cell type selected from the group consisting of: bone-marrow derived mesenchymal stem cells and adipose-derived mesenchymal stem cells. In embodiments, the one or more cell types comprises mesenchymal stem cells, the partially ordered polypeptide comprises at least one chemically-interactive sequence such as arginylglycylaspartic acid (RGD) sequence, the matrix forms a porous network when heated above a transition temperature, and the partially-ordered polypeptide comprises a plurality of structured domains, and a plurality of disordered domains.

The present invention addresses the problem of providing a novel therapeutic agent that is effective against diseases involving stratified squamous epithelial cells such as dry eye syndrome. The present invention is an agent for promoting normal differentiation / maturation of stratified squamous epithelial cells, which comprises a secretion of mesenchymal stem cells. It is preferable that the secretions not include animal serum, that the mesenchymal stem cells be adipose-derived mesenchymal stem cells, umbilical cord-derived mesenchymal stem cells, or bone marrow-derived mesenchymal stem cells, and that the stratified squamous epithelial cells be at least one selected from the group consisting of corneal epithelial cells, conjunctival epithelial cells, epidermal keratinocytes, oral epithelial cells, epiglottic epithelial cells, esophageal epithelial cells, vaginal epithelial cells, vocal fold epithelial cells, nasal epithelial cells, and nasal vestibular epithelial cells.

The invention discloses a preparation method and application of a novel macrophage for treating myocardial infarction, and belongs to the fields of cell engineering, nanotechnology, material science, immunology and the like. According to the invention, bone marrow-derived macrophages are induced to be polarized to M2 type and are subjected to magnetic modification, so that the macrophages are endowed with the capability of efficiently expressing vascular endothelial growth factors, Mag M2-M-VEGF cells are obtained, and proliferation of endothelial cells and formation of collateral vessels are promoted through local high expression of VEGF at a myocardial infarction part, so that local ischemia injury is relieved. According to the invention, precise targeted delivery of cells is realized, local inflammatory response is inhibited, and blood perfusion in an infarction area is improved. The medicine is endowed with magnetic targeting capacity by internalizing Fe3O4 NPs and is accurately enriched in myocardial infarction tissue under the guidance of a magnetic field, M2 type polarization inhibits pro-inflammatory reaction by reducing pro-inflammatory factor release and releasing a large amount of anti-inflammatory factors, and meanwhile, VEGF is specifically secreted, angiogenesis of an infarction part is promoted, and the capillary density of an infarction region is effectively increased.

The invention relates to the technical field of biology, and discloses an identification kit and an identification method for mouse tumor-associated macrophage subsets. The identification kit comprises a packaging box as well as a PBS (phosphate buffer solution) reagent bottle, a cell digestive juice reagent bottle, a red blood cell lysis buffer reagent bottle, an antigen confining liquid reagent bottle, a phycoerythrin (PE) labeled F4 / 80 antibody reagent bottle, a docoxanthin-chlorophyll-protein complex (PerCP) labeled CD68 antibody reagent bottle and fluorescein isothiocyanate (FITC) which are arranged in the packaging box and a labeled C1Q antibody reagent bottle. The identification kit can be used for identifying whether C1Q positive tumor-related macrophages appear in colorectal cancer tumor tissues or not; identifying whether the C1Q positive tumor-related macrophages are differentiated from bone marrow-derived macrophages or not; and identifying whether the C1Q positive tumor-associated macrophages are differentiated from tissue resident macrophages or not. According to the invention, the understanding of the innate immune cell subpopulation in the colorectal tumor immune microenvironment can be improved, and a new target spot is provided for diagnosis and treatment of colorectal cancer.

To provide adult neural stem cells and various adult pluripotent cells for the treatment of neurodegenerative diseases, new methods and compositions for treatment of neurodegenerative diseases.SOLUTION: Disclosed herein are methods and compositions for the use of marrow adherent stem cells and their descendants e.g. bone marrow-derived neural regenerating cells in the treatment of various neurodegenerative disorders. In certain embodiments, bone marrow-derived neural regenerating cells transplanted to sites of neural degeneration stimulate growth and / or survival of host neurons.SELECTED DRAWING: None

Disclosed are methods of treating perianal fistula a subject by administering a therapeutic MSC secretome product made by a method comprising culturing bone marrow-derived MSCs under conditions that include oxygen tension below 5% and a culture media with a pH below 7.

The invention discloses an immortalized goat bone marrow-derived macrophage for expressing an SV40LT gene and application of the immortalized goat bone marrow-derived macrophage, and belongs to the technical field of bioengineering. The immortalized goat bone marrow-derived macrophage provided by the invention is obtained by knocking an immortalized gene SV40LT into a primary goat bone marrow-derived macrophage ROSA26 site through a CRISPR-Cas 9 system, and the immortalized goat macrophage provided by the invention is an immortalized goat macrophage cell strain which is suitable for being infected with salmonella and brucella and can be continuously and stably passaged; the method can be effectively applied to immunological research on goat brucella infection resistance and production of brucella vaccines.

Disclosed are methods of treating perianal fistula a subject by administering a therapeutic MSC secretome product made by a method comprising culturing bone marrow-derived MSCs under conditions that include oxygen tension below 5% and a culture media with a pH below 7.

The present invention relates to a composition comprising C-C motif chemokine ligand 5 (CCL5) for promoting the activation of bone marrow-derived stem cells. It is identified that, when CCL5, which is a niche-enhancing factor, is injected together with growth related oncogene beta (GROβ), which is known to promote the mobilization of hematopoietic stem cells from the bone marrow into peripheral blood, and AMD3100, which is a CXCR4 antagonist, the migration of hematopoietic stem cells from bone marrow to peripheral blood increases, and the engraftment rate also increases when the hematopoietic stem cells are injected into recipients undergoing bone marrow transplantation. Therefore, the CCL5 protein, GROβ, and the CXCR4 antagonist AMD3100 are provided as a composition for promoting the activation of bone marrow-derived stem cells, and thus bone marrow-derived stem cells activated thereby is provided as a novel therapeutic means for bone marrow diseases requiring bone marrow transplantation.

Disclosed herein are methods of treating complex regional pain syndrome in a subject by administering a therapeutic MSC secretory group product prepared by a method comprising culturing a bone marrow-derived MSC under conditions comprising an oxygen tension of less than 5% and a culture medium having a pH of less than 7.

The present application discloses an evaluation model for idiosyncratic liver injury. The evaluation model includes the AIM2 inflammasome and components that promote the activation of the AIM2 inflammasome. Among them, the component that promotes bakuchiol as an immune promoter to induce the release of mitochondrial DNA, thereby leading to the activation of the AIM2 inflammasome is bakuchiol. The present application also provides a method for constructing the evaluation model. The construction method includes: preparing a solution of bakuchiol monomer samples; pretreating primary macrophages derived from mouse bone marrow with LPS and adding LPS for induction for 4 hours; adding the bakuchiol monomer solution to primary macrophages derived from mouse bone marrow for stimulation; performing Western blot to detect proteins related to the activation of the AIM2 inflammasome, ELISA to detect the release of inflammatory factors IL-1β and TNF-α, and performing statistical analysis.